Burden of Illness in CIDP: Results of a Multinational Real-World Survey
Author(s)
Swapna Karkare, MSc1, Clémence Arvin-Berod, Dr2, Febe Brackx, MSc3, Arash Mahajerin, Dr1, Dustin Nowacek, Dr1, Lucas Van de Veire, MA3, Rabiyah Sahar, MSc4, Yasmin Taylor, MBiol4, Jack Wright, MSc4, Jonathan James de Courcy, BSc4, Sarah Dewilde, PhD3.
1argenx US Inc., Boston, MA, USA, 2argenx BV, Ghent, Belgium, 3Services in Health Economics BV, Brussels, Belgium, 4Adelphi Real World, Bollington, United Kingdom.
1argenx US Inc., Boston, MA, USA, 2argenx BV, Ghent, Belgium, 3Services in Health Economics BV, Brussels, Belgium, 4Adelphi Real World, Bollington, United Kingdom.
Presentation Documents
OBJECTIVES: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare autoimmune disease associated with weakness and sensory symptoms, imposes a significant burden on patients. The aim of this analysis is to highlight treatment experience and quantify the disease burden in a multinational population.
METHODS: This is a secondary analysis of data from the Adelphi CIDP Disease Specific Programme™, a real-world, cross-sectional survey that collected physician- and patient-reported data across the US, the UK, France, Germany, Italy, Spain and Japan between September 2022-April 2023. Captured data included, among others, demographics, treatment history, employment status and use of a caregiver and mobility aids.
RESULTS: Patients (n=310) were, on average, 54.4 (SD: 12.6) years old, with 59% being male. At the time of survey, 81% (251/310) were receiving treatment with corticosteroids (114/251) and IVIg (100/251) most often prescribed followed by immunosuppressants (35/251) and biologics (29/251).
Despite available treatment options, moderate to severe symptoms were reported by 50% of patients (124/249). One third of patients (77/232) did not believe their CIDP was well-controlled with current treatment. Over half of patients (168/298) required mobility aids, most commonly a cane or walking stick (101/168). Nearly a third of patients (88/306) needed help with daily activities from a caregiver, usually a partner/spouse (74/87).
Among patients who were retired (64/307), unemployed (31/307), on long term sick leave (18/307) or working part time (26/307), almost half (61/130) reported that this was due to CIDP. Of those who were employed (full- or part-time), 27% (32/118) had missed time from work within the last 7 days due to CIDP (mean 6.8 hours).
CONCLUSIONS: Patients suffering from CIDP experience a significant burden, often despite receiving treatment. They continue to experience symptoms that affect their mobility and productivity, which leads some to rely on a caregiver for help.
METHODS: This is a secondary analysis of data from the Adelphi CIDP Disease Specific Programme™, a real-world, cross-sectional survey that collected physician- and patient-reported data across the US, the UK, France, Germany, Italy, Spain and Japan between September 2022-April 2023. Captured data included, among others, demographics, treatment history, employment status and use of a caregiver and mobility aids.
RESULTS: Patients (n=310) were, on average, 54.4 (SD: 12.6) years old, with 59% being male. At the time of survey, 81% (251/310) were receiving treatment with corticosteroids (114/251) and IVIg (100/251) most often prescribed followed by immunosuppressants (35/251) and biologics (29/251).
Despite available treatment options, moderate to severe symptoms were reported by 50% of patients (124/249). One third of patients (77/232) did not believe their CIDP was well-controlled with current treatment. Over half of patients (168/298) required mobility aids, most commonly a cane or walking stick (101/168). Nearly a third of patients (88/306) needed help with daily activities from a caregiver, usually a partner/spouse (74/87).
Among patients who were retired (64/307), unemployed (31/307), on long term sick leave (18/307) or working part time (26/307), almost half (61/130) reported that this was due to CIDP. Of those who were employed (full- or part-time), 27% (32/118) had missed time from work within the last 7 days due to CIDP (mean 6.8 hours).
CONCLUSIONS: Patients suffering from CIDP experience a significant burden, often despite receiving treatment. They continue to experience symptoms that affect their mobility and productivity, which leads some to rely on a caregiver for help.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD168
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Neurological Disorders, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)